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INTRODUCTION
There is growing evidence that links DNA methylation to the development of human cancer (1) (2) (3) (4) . DNA hypermethylation to repress transcription of genes encoding tumor suppressors (5, 6) , cell cycle regulators (7), DNA repair enzymes (8, 9) , and hormone receptors (10) has been well documented and is being actively studied. However, it is much less known about the loss of this epigenetic control to reactivate transcription of tissue-restricted genes in the development of human cancer.
Synuclein-gamma (SNCG), also named BCSGI (Breast Cancer Specific Gene 1) is a member of a neuronal protein family synuclein, consisting of synuclein-alpha (SNCA), synuclein-beta (SNCB), and SNCG (11) (12) (13) . Although this group of proteins is abundantly expressed in brain tissues, their normal cellular functions have not been clearly defined, which is in contrast to the well-known pathological roles of synucleins in a number of human diseases. SNCA is the major component of Lewy bodies in sporadic Parkinson's disease and in a subtype of Alzheimer's disease (14, 15) . Mutations of SNCA have been detected in several familial cases of Parkinson's disease (16) . SNCA peptide also has been identified as the nonamyloid component of amyloid deposition, the hallmark of Alzheimer's disease (17, 18) . Interestingly, SNCG shares 54% sequence identity with SNCA (19), SNCG is not clearly involved in neurodegenerative diseases. Instead, SNCG has been implicated in human neoplastic diseases, particularly in breast cancer and ovarian cancer. Several studies have shown that SNCG was abnormally expressed in a high percentage of advanced and metastatic breast tumors but not in normal or benign breast tissues (19) (20) (21) . When overexpressed, SNCG stimulates proliferation and induces metastasis of breast cancer cells (22) (23) (24) (25) (26) . Analysis of breast tumor samples did not identify any sequence variation of SNCG gene from its original normal neuronal environment and no gene amplification was detected either (27) , suggesting that transcriptional activation could account for its abundant expression in breast cancer cells. By analyzing the promoter region of SNCG gene and conducting genomic sequencing we had demonstrated that the loss of methylation control in a CpG island located in exon 1 of SNCG was primarily responsible for the aberrant expression of this neuronal protein in breast carcinoma (28) and in some ovarian carcinomas (29) . Further investigations aimed to elucidate the oncogenic functions of this protein have revealed that SNCG overexpression in breast cancer cells resulted in a compromised mitotic checkpoint (30) , increased resistance of tumor cells to anti-microtubule drugs (31) , and accelerated rate of chromosomal instability (32) . Since the mitotic checkpoint control is critical for every cell type to maintain its genetic stability (33, 34) , the inhibitory effects of SNCG on mitotic checkpoint function imply that the abnormal expression of SNCG in human tissues outside the neuronal system could have general tumorigenic effects and SNCG may play a profound oncogenic role in human cancers beyond breast or ovarian carcinogenesis. However, SNCG protein expression and methylation status of the CpG island in other human cancers have not been carefully examined. Furthermore, the initial observation of augmentation of tumor cell metastasis by SNCG expression obtained in an animal model of breast cancer (22) has not been corroborated by clinical evidence.
In the current study, we independently examined the protein expression and the methylation status of SNCG gene in 320 patient samples of malignant and matched non neoplastic adjacent tissues (NNAT) derived from 8 diversified cancer types, including male-specific prostate cancer, female-specific cervical cancer, 4 cancer types in digestive system (liver, esophagus, stomach, colon) and an respiratory specific cancer (lung cancer); patient samples of breast carcinoma were also included in this study to serve as positive controls. The relationships between SNCG protein expressions with all clinicopathological features of cancer patients were further analyzed in great details to identify significant correlations.
BODY

Specific expressions of SNCG protein in different malignant tumor tissues but not in normal counterparts
Archived tumor tissues and the matched non neoplastic adjacent tissues from 160 patients diagnosed with a variety of cancer types were examined for SNCG protein expression by immunohistochemistry (IHC). Out of 160 tumor samples, 108 (67.5%) samples displayed clear intracellular staining of SNCG protein exclusively in their malignant cells at different expression levels and with a frequency that varied by cancer type: liver (19/20) , esophagus (16/20) , prostate (15/20) , cervical (14/20) , gastric (13/20) , colon (12/20) , breast (10/20) , and lung (9/20) . By a sharp contrast, only 4 out of 160 tissue samples adjacent to tumors from the same patient cohort showed low immunoreactivity with anti-SNCG antibody (0.6%). Normal tissues of liver, esophagus, prostate, cervix, stomach, and breast of healthy subjects were all negative in IHC of SNCG. These results provide the first evidence for predominant expressions of SNCG protein in a wide range of human cancers but not expressed in their normal counterparts.
Detection of demethylation of SNCG CpG island in malignant and non neoplastic adjacent tissues
To determine whether SNCG expressions in tumor tissues correlate with the demethylation of SNCG gene, the methylation status of the CpG island of SNCG in tumor and NNAT samples was examined by a nested, two-step MSP assay in combination with direct in vivo sequencing of bisulfite modified genomic DNA isolated from paraffin-embedded fixed tissues of the same patient cohort. Initially, to verify the specificity of the primer pairs that distinguish the CpG sites from unmethylated TpG dinucleotides within the CpG island, the methylated and unmethylated PCR products from one pair of liver tumor/NNAT and one pair of lung tumor/NNAT samples were cloned into pCR2.1 TOPO cloning vector. After transformation, plasmid DNAs isolated from multiple clones of each DNA sample were sequenced. The CpG sites were shown methylated in all clones amplified using methylated primers and were converted to TpG dinucleotides in clones amplified using demethylated primers. With this solid validation of primer specificity and PCR conditions, the MSP method was used to examine the SNCG CpG island in 320 DNA samples of tumor and NNAT blindly without knowing the expression status of SNCG protein. Demethylated PCR product of SNCG CpG island, either as the sole form or as the predominant form when compared with the methylated PCR product from the same DNA sample, was detected in every tumor sample across all cancer types (100%), indicating a universal loss of the epigenetic control of SNCG gene in tumors. In addition to tumor samples, the 4 NNAT samples that were shown positive in -IHC examination with anti-SNCG antibody also contain demethylated SNCG gene. These results clearly demonstrate that the demethylation of SNCG CpG island is primarily responsible for the aberrant expression of SNCG protein in many solid tumors.
In addition to changes observed in tumor tissues, MSP detected demethylated alleles of SNCG in a substantial population of NNAT samples in a tumor-type specific manner. In lung, prostate, and gastric cancers, the SNCG CpG island remained predominantly methylated and demethylation rarely occurred in NNAT samples. The frequency of demethylation in NNAT samples was modest in esophagus and colon cancer. However, significant percentages (40-45%) of NNAT samples of liver, breast, and cervical cancer patients contained demethylated gene at relatively high abundance. By performing exact Chi-square test to evaluate the relationship between SNCG protein expression with the methylation status, we found a close association between the SNCG protein expression in tumor samples with the demethylation of SNCG CpG island in tumor adjacent non neoplastic tissues (p<0.001). Among 108 tumor samples that expressed SNCG protein, partial demethylation occurred in 45 samples of their non malignant counterparts (41.7%). In contrast, SNCG demethylation was detected only in 3 out of 52 NNAT samples (5.7%) to which their matched tumor samples were negative in SNCG protein expression.
Assessment of methylation patterns of SNCG CpG island in different tissues by genomic sequencing
In order to obtain detailed methylation versus demethylation patterns of SNCG CpG island in different malignant and non malignant tissues, with the guidance of MSP results, modified DNAs of two pairs of patient samples from each cancer type that displayed demethylated SNCG in tumor and methylated SNCG in matched NNAT were selected for genomic sequencing. The results show that nearly all CpG sites within the CpG island of SNCG were demethylated in all cancer types; conversely, almost all CpG sites were remained methylated in the matched normal tissues with an exception of normal breast tissues that showed a pattern of partial demethylation at certain CpG sites, consistent with our previous findings (28, 29) . From these sequencing results we conclude that SNCG CpG island is fully methylated in normal tissues of liver, esophagus, prostate, cervix, stomach, colon, and lung but partially methylated in breast tissue. Tumors from these tissues contain completely demethylated SNCG.
There are at least two possible reasons to explain the appearance of demethylated alleles in some NNAT samples, particularly in those samples that their malignant counterparts expressed SNCG protein. One possibility is that a small amount of tumor cells might have infiltrated into adjacent tissues and contributed to the demethylated SNCG alleles appeared in NNAT samples. The alternative possibility is that the demethylation event of SNCG CpG island precedes malignant transformation in the tumor neighboring cells. To examine these possibilities, we performed genomic sequencing to a number of NNAT samples in which demethylated alleles were detected by MSP. The sequencing data in Fig. 3B revealed that unlike tumor tissues where the CpG islands of SNCG were completely demethylated, the CpG island of SNCG from all NNAT samples were only partially demethylated at certain CpG sites. Completely demethylated alleles were not found at all. These results ruled out the possibility of tumor cell infiltration and provided direct evidence indicating the occurrence of ongoing genetic changes in these tumor neighboring cells that appeared morphologically normal at the time of surgery.
Associations of SNCG protein expression with disease progression and distant metastasis
In a previous study, the expression of SNCG in MDA-MB435 cells resulted in a massive metastasis of breast cancer cells to lung in nude mice (22) , indicating a positive role of this oncogene product in metastasis.
To obtain direct clinical evidence, we analyzed clinicopathological features of all patients with relationships to SNCG protein expression status. Significant correlations of SNCG protein expression with advanced stages of tumor were observed in all cancer types. In liver, esophagus, prostate, cervical, breast, and lung cancers, patients with diseases of stages II-V all expressed SNCG protein (100%). SNCG positivity was also high at 81.2% and 78.5% in gastric and colon cancers. In contrast, SNCG protein was only detected in 20% or less of patient samples with diseases at stage I or stage 0 from esophagus, prostate, breast, gastric, or colon cancers.
A relatively higher percentage (50%) of stage I samples from cervical cancer (6/12) and liver cancer (1/2) expressed SNCG protein.
The correlation of SNCG protein expression with lymph node invasion was found in prostate, breast, and lung cancers. The correlations of SNCG protein expression with lymph node invasion in liver, esophagus, gastric, cervical, and colon cancer were not statistically significant due to the lack of sufficient cases of lower stages of patient samples. However, we found that the SNCG protein expression in primary carcinomas of different cancer types were all strongly associated with distant metastasis (p<0.001) with an exclusion of cervical cancer, in which tumors were removed from patients before tumor spread. In liver, esophagus, prostate, colon, breast, and lung cancer, patients with distant metastasis all expressed SNCG protein in their primary carcinomas, and 12/14 metastatic gastric patients were also SNCG-positive. Overall, out of 94 SNCG-positive primary carcinomas, metastasis was found in 57 cancer patients; in contrast, only 2 out of 46 SNCG-negative tumor samples were from the patients with metastatic cancers (60.6% vs. 4%, p<0.001). These results reveal a strong association between SNCG protein expression and tumor distant metastasis.
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tumor/nonneoplastic adjacent tissue samples were cloned into pCiI2.1 TOPO cloning vector. After transformation, plasmid DNAs isolated from multiple clones of each DNA sample were sequenced. The CpG sites were shown methylated in all clones amplified using SNCG gene. These results clearly show that the demethylation of methylated primers and were converted to TpG dinucleotides in SNCG CpG island is primarily responsible for the aberrant clones amplified using demethylated primers ( Fig. 2A, bottom) , expression of SNCG protein in many solid tumors. With this solid validation of primer specificity and PCR conditions, In addition to changes observed in tumor tissues, MSP-detected the MSP method was used to examine the SNCG CpG island in 320 demethylated alleles of SNUG in a substantial population of DNA samples of tumor and nonneoplastic adjacent tissue blindly, nonneoplastic adjacent tissue samples in a tumor type-specific without knowing the expression status of SNCG protein. Repremanner. In lung, prostate, and gastric cancers, the SNCG CpG sentative results of five pairs of DNA samples from each cancer island remained predominantly methylated and demethylation type are shown in Fig. 2B-D and all results are summarized in rarely occurred in nonneoplastic adjacent tissue samples (Fig. 2B) . Table 2 . Demethylated PCR product of SNCG CpG island, either as
The frequency of demethylation in nonneoplastic adjacent tissue the sole form or as the predominant form when compared with the samples was modest in esophagus and colon cancer (Fig. 2C) . methylated PCR product from the same DNA sample, was detected Hlowever, significant percentages (40-45%) of nonneoplastic in every tumor sample across all cancer types (100%), indicating a adjacent tissue samples of liver, breast, and cervical cancer patients universal loss of the epigenetic control of SNCG gene in tumors. In contained demethylated gene at relatively high abundance addition to tumor samples, the four nonneoplastic adjacent tissue (Fig, 2D) . By performing exact X12 test to evaluate the relationship samples that were shown positive in immunohistochemistry between SNCG protein expression with the methylation status, we examination with anti-SNCG antibody also contain demethylated found a close association between the SNCG protein expression
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SNCG Gene as a Molecular Indicator of Metastasis
in tumnor samples with the demethylation of SNTCG CpG island in each cancer type that displayed demethylated SNCG in t umor and tumor adjacent nonneoplastic tissues (P < 0.001). Among methylated SNCO in matched nonneoplastic adjacent tissue were 108 tumor samples that expressed SNCG protein, partial demethyselected for genomic sequencing (Fig. 3A) . Nearly all CpG sites F3 lation occurred in 45 samples of their nonmalignant counterparts within the CpG island of SNCG were demethylated in all canicer (41.7%). In contrast, SNCG demethylat~ion was detected only in 3 of types; conversely, almost all CpG sites were remained meth "ylated inl 52 nonneoplastic adjacent tissue samples (5.7%) to which their the matched normal tissues with an exception of normal breasti matched tumor samples were negative in SNCG protein expression.
tissues that showed a pattern of partial demethylation at certain Assessment of methylation patterns of SNCG CpG island in CpG sites, consistent with our previous findings (28, 29). trom these different tissues by genomic sequencing. 'To obtain detailed sequencing results, 'we conclude that, SNCG CpG island is fully methylation versus demethylation patterns of SNCG CpG island in methylated in normal tissues of liver, esophagus, prostate, cervix, different malignant and nonmalignant tissues, with the guidance of stomach, colon, arnd lung but partially methylated in breast tissue, MSP results, modified 1JNAs of two pairs of patient samples From Tumors from these tissues contain completely demethylated SNCG.
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www.aacrjournals.org samples were from the patients with metastatic cancers (60.6% and methylated SNCG in matched nonneoplasfic adjacent tissue (N) was versus 4%, P < 0.001; Table 4 ). These results reveal a strong T4 selected for genomec sequencing; the selected tumor samples were negative in association between SNCG protein expression and tumor distant SNCG protein expression, In (B), DNAs of two nonneoplastic adjacent tissue samples that displayed demeihylated SNCG in assays of MSP and their tumor metastasis. counterparts expressed SNCG protein were selected for each cancer type.
05-1089
Discussion
There are at least two possible reasons to explain the appearance SNCG gene was previously considered breast cancer specific and of demethylated alleles in some nonneoplastic adjacent tissue was named as breast cancer specific gene I (BCSGI) due to its high samples, particularly in those samples that their malignant expression in breast carcinomas and its shown ability in inducing counterparts expressed SNCG protein. One possibility is that a breast cancer cells to proliferate and metastasis. In this study, we small amount of tumor cells might have infiltrated into adjacent provide direct evidence that shows a broad expression spectrum of tissues and contributed to the demethylated SNCG alleles that this oncogene product in different cancers, thereby reinforcing the appeared in nonneoplastic adjacent tissue samples. The alternative importance of SNCG in human malignancy. Several major new possibility is that the demethylation event of SNCG CpG island findings of this current study significantly extend the previous precedes malignant transformation in the tumor neighboring cells, understanding of the pathologic role of this neuronal protein in To examine these possibilities, we did genotnic sequencing to a human neoplastic diseases. number of nonneoplastic adjacent tissue samples in which
We show that SNCG protein is highly expressed in diversified demethylated alleles were detected by MSP. The sequencing data cancer types, including the female hormone-sensitive cervical and in Fig. 3B revealed that unlike tumor tissues where the Cp( islands breast cancers, male hormone-sensitive prostate cancer, four of SNCG were completely demethylated, the CpG island of SNCG cancer types of the digestive system, and lung cancer. the leading from all nonneoplastic adjacent tissue samples were only partially cause of mortality in both men and women. It is noteworthy that demethylated at certain CpG sites. Completely demethylated during the course of this investigation, SNCG protein expression in alleles were not found at all. These results ruled out the possibility gastric cancer (36) and pancreatic cancer (37, 38) were also of tumor cell infiltration and provided direct, evidence indicating detected by independent research groups. Combined with previous (22) , the direct clinical evidence of chemistry, -, negative of SNCG protein expression by immunohistoa role of SNCG in tumor metastasis was lacking Our current studies chemistry. Tumors were staged following standard AJCC/UICC TNM reveal a strong correlation between SNCG expression in primary methodology, tumors and distant metastasis in patients of all cancer types. Our *P < 0.001.
findings not only corroborate the data from animal studies to some extent but also further suggest that SNCG expression status can be considered as a pathologic indication to predict the propensity of stages of disease is a common feature in this study and in previous metastasis to distant organs and aid in guidance for designing reports. Our results are consistent with the notion that SNCG optimized and individualized therapeutic regimens for patients promotes disease progression (19, 22) . f1ow SNCG induces disease when the tumor samples are available after surgeries. progression in different cancer types remains elusive. In breast Taken together, our new findings strongly suggest that the loss of cancer cells, SNCG has been shown to act as a chaperon for epigenetic control of the neuron-restricted expression of SNCG estrogen receptor and stimulate estrogen receptor-n signaling gene is likely a common critical contributing factor to malignant pathway that leads to cell proliferation (25, 26) . On the other hand, progression of different types of human cancer, and that the strong we have shown that the inhibitory effects of SNCG on mitotic association of SNCG protein expression in primary carcinomas checkpoint function are mediated through the mitotic checkpoint with distant metastasis marks this protein an effective molecular kinase BubR1 and are independent of the expression status of indicator of tumor metastasis. estrogen receptor-a (30 
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